Healios K.K Past Earnings Performance
We're still processing the latest earnings report of this company
Past criteria checks 0/6
Healios K.K has been growing earnings at an average annual rate of 5.7%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 82.1% per year.
Key information
5.7%
Earnings growth rate
17.0%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 82.1% |
| Return on equity | -164.8% |
| Net Margin | -1,034.4% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Healios K.K makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 521 | -5,389 | 1,203 | 2,376 |
| 31 Mar 24 | 124 | -5,515 | 1,143 | 2,443 |
| 31 Dec 23 | 121 | -3,823 | 1,116 | 2,304 |
| 30 Sep 23 | 174 | -3,305 | 1,162 | 2,312 |
| 30 Jun 23 | 176 | -3,301 | 1,244 | 2,519 |
| 31 Mar 23 | 86 | -4,441 | 1,374 | 3,265 |
| 31 Dec 22 | 90 | -5,169 | 1,378 | 3,808 |
| 30 Sep 22 | 41 | -5,172 | 1,392 | 4,169 |
| 30 Jun 22 | 43 | -6,278 | 1,467 | 4,495 |
| 31 Mar 22 | 43 | -5,341 | 1,428 | 3,946 |
| 31 Dec 21 | 41 | -4,910 | 1,649 | 3,700 |
| 30 Sep 21 | 36 | -5,192 | 1,580 | 3,500 |
| 30 Jun 21 | 33 | -4,796 | 1,494 | 3,230 |
| 31 Mar 21 | 29 | -5,278 | 1,437 | 3,175 |
| 31 Dec 20 | 27 | -5,512 | 1,155 | 2,986 |
| 31 Dec 14 | 279 | -480 | 804 | 0 |
Quality Earnings: HLOS.F is currently unprofitable.
Growing Profit Margin: HLOS.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: HLOS.F is unprofitable, but has reduced losses over the past 5 years at a rate of 5.7% per year.
Accelerating Growth: Unable to compare HLOS.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HLOS.F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: HLOS.F has a negative Return on Equity (-164.78%), as it is currently unprofitable.